Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

GLAXOSMITHKLINE : Goldman Sachs keeps its Buy rating

share with twitter share with LinkedIn share with facebook
07/16/2020 | 07:40am EDT

In his latest research note, analyst Keyur Parekh confirms his positive recommendation. The broker Goldman Sachs is keeping its Buy rating. The target price is unchanged and still at GBX 2060.

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -2.17% 1535.8 Delayed Quote.-11.76%
THE GOLDMAN SACHS GROUP, INC. -0.20% 207.97 Delayed Quote.-7.74%

© MarketScreener with dpa-AFX Analyser 2020
share with twitter share with LinkedIn share with facebook
Toute l'actualité sur GLAXOSMITHKLINE PLC
03:22pCOVID-19 vaccine developer CureVac shares more than triple after U.S. debut
RE
01:13pCOVID-19 vaccine developer CureVac shares more than triple after U.S. debut
RE
12:28pGLAXOSMITHKLINE : COVID-19 vaccine developer CureVac shares more than triple aft..
RE
12:00pVaccine makers including Moderna must hit U.S. timing goals for full payments
RE
11:36aEU Secures Coronavirus Vaccine Deal With AstraZeneca
DJ
10:14aVaccine makers including Moderna must hit U.S. timing goals for full payments
RE
08/13EU to enter contract talks with J&J over 200 million doses of potential COVID..
RE
08/13EUROPE : European stocks end four-day winning run as UK's FTSE drags
RE
08/13GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
FA
08/12GLAXOSMITHKLINE : UBS maintains a Buy rating
MD
More news
Financials
Sales 2020 35 040 M 45 867 M 45 867 M
Net income 2020 4 781 M 6 258 M 6 258 M
Net Debt 2020 22 747 M 29 776 M 29 776 M
P/E ratio 2020 14,9x
Yield 2020 5,21%
Capitalization 76 434 M 100 B 100 B
EV / Sales 2020 2,83x
EV / Sales 2021 2,70x
Nbr of Employees 99 437
Free-Float 91,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 1 867,21 GBX
Last Close Price 15,36 GBX
Spread / Highest target 14 485%
Spread / Average Target 12 058%
Spread / Lowest Target 9 908%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-11.76%102 218
JOHNSON & JOHNSON2.60%389 658
ROCHE HOLDING AG0.45%296 698
PFIZER, INC.-2.58%212 106
MERCK & CO., INC.-8.15%211 293
NOVARTIS AG-15.35%188 399